The neuropeptide Y Y5 receptor gene generates two splice variants, referred to here as Y5 L (long isoform) and Y5 S (short isoform). Y5 L mRNA differs from Y5 S mRNA in its 5h end, generating a putative open reading frame with 30 additional nucleotides upstream of the initiator AUG compared with the Y5 S mRNA. The purpose of the present work was to investigate the existence of the Y5 L mRNA. The authenticity of this transcript was confirmed by isolating part of its 5h untranslated region through 5h rapid amplification of cDNA ends and analysing its tissue distribution. To study the initiation of translation on Y5 L mRNA, we cloned the Y5 L cDNA and two Y5 L cDNA mutants lacking the first or the second putative initiation start codon. Transient expression of the three plasmids in COS-7 cells and saturation binding experiments using "#&I-labelled polypeptide YY (PYY) as a ligand showed that initiation of translation on Y5 L mRNA could start at the first AUG, giving rise to a Y5 L receptor with an N-terminal 10-amino-acid extension
Molecular identification of the long isoform of the human neuropeptide Y Y5 receptor and pharmacological comparison with the short Y5 receptor isoform
The neuropeptide Y Y5 receptor gene generates two splice variants, referred to here as Y5 L (long isoform) and Y5 S (short isoform). Y5 L mRNA differs from Y5 S mRNA in its 5h end, generating a putative open reading frame with 30 additional nucleotides upstream of the initiator AUG compared with the Y5 S mRNA. The purpose of the present work was to investigate the existence of the Y5 L mRNA. The authenticity of this transcript was confirmed by isolating part of its 5h untranslated region through 5h rapid amplification of cDNA ends and analysing its tissue distribution. To study the initiation of translation on Y5 L mRNA, we cloned the Y5 L cDNA and two Y5 L cDNA mutants lacking the first or the second putative initiation start codon. Transient expression of the three plasmids in COS-7 cells and saturation binding experiments using "#&I-labelled polypeptide YY (PYY) as a ligand showed that initiation of translation on Y5 L mRNA could start at the first AUG, giving rise to a Y5 L receptor with an N-terminal 10-amino-acid extension
INTRODUCTION
Neuropeptide Y (NPY) is a 36-amino-acid peptide belonging to the pancreatic polypeptide family, which also includes polypeptide YY (PYY) and pancreatic polypeptide (PP) [1] . NPY is one of the most abundant and widely distributed neurotransmitters in both the central and peripheral nervous systems [2] . Chronic administration of NPY into the lateral ventricle or direct injection into the paraventricular nucleus of the rat increases food intake and lead to obesity [3, 4] . In addition to its orexigenic action, NPY modulates numerous physiological processes, including anxiety, anti-convulsant activity, blood pressure, memory retention, circadian rhythms and gastrointestinal function [5] [6] [7] [8] [9] [10] . These diverse physiological actions are mediated through distinct NPY receptor subtypes, all of which are coupled to G-proteins, and their activation leads to the inhibition of adenylate cyclase. To date, five NPY receptors, designated Y1, Y2, Y4, Y5 and Y6, have been cloned from human and rodent tissues (reviewed by Blomqvist and Herzog [11] ). Among these, the NPY Y1 and NPY Y5 receptors are regarded as putative Key words : initiation codon context, NPY receptor, obesity, translation, 5h untranslated region.
receptor subtypes that mediate the appetite-stimulating action of NPY [12] [13] [14] [15] [16] [17] .
Initial cloning of the Y5 receptor in humans identified two alternatively spliced Y5 mRNA transcripts [15, 18, 19] . Sequence comparison of the corresponding cDNAs indicated divergence in their 5h untranslated regions (UTRs) and 5h end coding regions. Gerald et al. [15] reported a cDNA encoding a predicted 455-amino-acid receptor, whereas the Y5 cDNA described by Hu et al. [18] encoded a shorter 445-amino-acid version of the receptor lacking the 10 N-terminal amino acids. We thus designated the longer and the shorter forms of the receptor Y5 L and Y5 S respectively. Parker and Xia [20] showed evidence for extensive alternative splicing in the 5h UTR of the Y5 receptor gene. Five human NPY Y5 receptor cDNAs splice variants, all of which encoded the short form of the Y5 receptor, were isolated by performing 5h rapid amplification of cDNA ends (RACE) from brain poly(A + ) RNA. Moreover, while we and others [21, 22] reported the cloning and the expression of the Y5 L form, Parker et al. [23] explained their unsuccessful attempts to express the Y5 L receptor by suggesting that nucleotides 1-55 of the sequence reported by Gerald et al. [15] arise from the NPY Y5 receptor gene and are not actually found in human Y5 cDNA transcripts.
In view of this controversy, the purpose of the present work was to investigate the existence of the Y5 L mRNA. The authenticity of this transcript was indeed confirmed by isolating part of its 5h UTR through 5h RACE and analysing its tissue distribution. Moreover, we provide evidence that initiation of translation on the Y5 L mRNA can give rise to a functional receptor with an N-terminal 10-amino-acid extension when compared with the Y5 S receptor, and that the two AUG triplets contained in the 5h UTR did not affect receptor expression. Finally, we show that the Y5 L and Y5 S receptor isoforms display similar pharmacological profiles.
MATERIALS AND METHODS

5h RACE
PCR was carried out with Clontech Human Hypothalamus Marathon-Ready cDNA as a template, according to the manufacturer's instructions (Clontech, Palo Alto, CA, U.S.A.). In the first PCR reaction, cDNA was amplified with the abridged anchor primer AP1 and a reverse primer based on a region common to the Y5 S and Y5 L sequences (nucleotides 354-383 ; GenBank accession no. U56079). The resulting PCR products were then submitted to Southern blotting with internal specific oligonucleotide probes based on unique regions of the Y5 L (OP1 ; nucleotides 18-40 ; accession no. U56079) and Y5 S (OP2 ; nucleotides 39-61 ; accession no. U94320) sequences. For nested PCR, the primary PCR product was subjected to 25 cycles of amplification using the abridged anchor primer AP2 and a reverse primer based on a region common to the Y5 S and Y5 L sequences (nucleotides 296-322 ; accession no. U56079). The RACE products were then subcloned into pT-Adv (Clontech).
Analysis of expression by reverse transcription-PCR (RT-PCR)
RNA from human hypothalamus was obtained from Analytical Biological Services (Wilmington, DE, U.S.A.), and RNA from human hippocampus and caudate nucleus was obtained from Clontech. RNAs were reverse transcribed using oligo-(dT) "# -") and Superscript II reverse transcriptase (Invitrogen). The first-strand cDNA (corresponding to 1 µg of total RNA) was amplified using a program consisting of 30 cycles of 94 mC for 1 min, 55 mC for 1 min and 72 mC for 3 min, with pre-and post-incubation steps of 94 mC for 1 min and 72 mC for 5 min respectively. PCR amplification utilized forward primers based on unique regions of the Y5 L (nucleotides 18-40 ; accession no. U56079) and Y5 S (nucleotides 39-61 ; accession no. U94320) sequences and a reverse oligonucleotide primer (SD5) based on a region common to the Y5 S and Y5 L sequences (nucleotides 364-383 ; accession no. U56079). PCR products were separated by agarose (1 %, w\v) gel electrophoresis and transferred to a Hybond N + membrane (Amersham Pharmacia Biotech). Hybridization was performed at 42 mC with internal specific Y5 $#P-labelled oligonucleotide probe (nucleotides 56-77 ; accession no. U56079).
Construction of recombinant plasmids
Poly(A + ) RNA from human brain caudate nucleus (Clontech) was reverse transcribed with oligo(dT) "# -") using Superscript II reverse transcriptase. First-strand cDNA (corresponding to 1 µg of total RNA) was amplified using a program consisting of 35 cycles of 94 mC for 1 min, 55 mC for 1 min and 72 mC for 3 min, with pre-and post-incubation steps of 94 mC for 1 min and 72 mC for 7 min respectively. PCR amplification utilized oligonucleotide primers based on GenBank entries for either human Y5 L (forward 18-40, reverse 1377-1399 ; accession no. U56079) or human Y5 S (forward 51-73, reverse 1377-1399 ; accession no. U56079). The expected PCR fragments were isolated and ligated into the Okayama and Berg [24] expression vector pSR. The recombinant plasmids pY5 S and pY5 L were sequenced on both strands by automated sequencing.
To study the initiation of translation on Y5 L mRNA, two Y5 L cDNA mutants lacking the first or the second putative initiation start codon were constructed by PCR cloning. The mutant MATG1 had the first ATG codon (nucleotides 26-28 ; accession no. U56079) mutated to GTG. The mutant MATG2 had the second ATG codon (base 56-58 ; accession no. U56079) mutated to GTG. The template used in PCR was the plasmid pY5 L described above. The expected PCR fragments were isolated and ligated into the Okayama and Berg [24] expression vector pSR. After subcloning, the presence of the indicated mutations was confirmed by automated DNA sequencing.
To study the effects of upstream AUG codons on Y5 L mRNA translation, the Y5 L coding region flanked by 50 bp from the 5h UTR was amplified from human brain caudate nucleus cDNA by PCR with nucleotide primers (5h GAATAGATTAATTTA-AAGTAGTCA 3h) and (5h GAATTATTACATATGAAGAC-AGT 3h). The expected PCR fragment was isolated and ligated into the expression vector pSR. The recombinant plasmid pUY5 L was sequenced on both strands by automated sequencing. The mutant pUY5 L 1 had the first ATG codon (see Figure 1B ) mutated to GTG. The mutant pUY5 L 2 had the second ATG codon (see Figure 1B ) mutated to GTG. The templates used in PCR were the plasmids pUY5 L and pUY5 L 1 described above. The expected PCR fragments were isolated and ligated into the expression vector pSR. After subcloning, the presence of the indicated mutations was confirmed by automated DNA sequencing.
Receptor expression
COS-7 cells grown in Dulbecco's modified Eagle's medium containing 10 % (v\v) fetal calf serum were seeded at 15i10' cells per 225 ml culture flask, and transfected 24 h later with 25 µg of plasmid, using AMINE TM as described by the manufacturer (Life Technologies). Cells were scraped 48 h after transfection into lysis buffer (20 mM Tris\HCl, pH 7.7, containing 5 mM EDTA), and membranes were prepared for binding assays.
Preparation of cell membranes
The suspension was homogenized using a Kinematica polytron and then centrifuged at 43 000 g (30 min, 4 mC). The resulting pellet was resuspended in binding buffer (see below) without BSA at a concentration of 5 mg\ml. Aliquots of membrane preparation were stored at k80 mC until use. 0.1 % polyethyleneimine, followed by three successive washes with 50 mM Tris\HCl, pH 7.4.
cAMP response element (CRE)-luciferase reporter assay
The p∆MC16-Luc plasmid (provided by Dr J. Bockaert, UPR CNRS 9023, Montpellier, France), which contains the luciferase coding sequence driven by a thymidine kinase promoter flanked by 16 cAMP response elements (CREs), and the pcDOR8 plasmid (provided by P. Morgan, Rowett Research Institute, Aberdeen, Scotland), encoding the expression of the ovine MC5 melanocortin receptor, have been described previously [25, 26] . This method is an adaptation of the method described by Conway et al. [27] for the characterization of the human melatonin receptors. HEK cells, cultured to " 80 % confluence, were transfected with AMINE Plus TM (Life Technologies) using 20 ng of pcDOR8, 500 ng of p∆MC16-Luc and 1 µg of either pY5 L or pY5 S per 10' cells. At 24 h after transfection, cells were detached by agitation, centrifuged (12 000 g, 10 min) and recovered at 10' cells\ml in Phenol Red-free Dulbecco's modified Eagle's medium supplemented with 2 % (v\v) fetal calf serum. They were then seeded as 50 µl aliquots into white 96-well tissue culture plates. The cells were treated first with [Nle%--Phe(]α-melanocyte-stimulating hormone (α-MSH ; 10 nM), and then with increasing concentrations of NPY (10 pM-1 µM). After a 20 h incubation period, luciferase activity was measured by adding 100 µl per well of Luclite buffer (Packard, Meriden, CT, U.S.A.) following by a 30 min incubation in the dark at room temperature, and fluorescence was read using a TopCount plate reader (Packard).
Chemicals
All peptide reference compounds were obtained from NeoSystem (Strasbourg, France) or Bachem (Basel, Switzerland). Banyu 6 is compound 6 described by Fukami et al. [28] , and Synaptic 34 is compound 34 described by Islam et al. [29] .
Data analysis
Binding data were generated as duplicate values within each experiment, which were repeated independently at least three times. Saturation analysis was analysed using the program PRISM (GraphPad Software Inc., San Diego, CA, U.S.A.) to yield K D (the dissociation constant of the radioligand) and B max (the maximal number of binding sites). Displacement curve fittings were generated by non-linear regression to yield IC &! values (concentration of compound giving 50 % inhibition of ["#&I]PYY binding). Inhibition constants (K i ) were calculated according to the Cheng-Prusoff equation : 
RESULTS AND DISCUSSION
Identification of the Y5 L transcript
In order to confirm the authenticity of the Y5 L transcript, 5h RACE was conducted using human hippocampus MarathonReady cDNA as a template. PCR was performed with the forward adapter AP1 primer and a reverse primer based on a region common to the Y5 S and Y5 L sequences. The PCR products were then characterized by Southern blotting with two oligonucleotide probes : OP1, based on a unique region of the Y5 L sequence, and OP2, based on a region common to four out of the five Y5 S transcripts described by Parker and Xia [20] . As shown in Figure 1(A) , bands ranging in size between 400 and 920 bp were detected with the OP1 probe, whereas two bands with approximate sizes of 420 bp and 750 bp were found with the OP2 probe. To further characterize the 5h UTR of the Y5 L mRNA, the resulting PCR products were cloned. This initial attempt was unsuccessful, as no clone was detected by hybridization with the
Figure 2 Distribution of Y5 L and Y5 S mRNAs in human tissues
cDNAs from different brain regions (A) and peripheral tissues (B) were used as templates for PCR amplification. Two sets of primers, OP1-SD5 and OP2-SD5, were designed to amplify fragments that are unique to the Y5 L and Y5 S sequences respectively. The PCR products were run on a 1 % (w/v) agarose gel, transferred to a Hybond N + membrane, and hybridized with a specific 32 P-labelled oligonucleotide probe. RT -indicates control experiments lacking reverse transcriptase.
OP1 probe. Therefore a second round of PCR was performed using nested primers. The resulting PCR products were cloned and three positively hybridizing clones were isolated. The sequence of the clone with the longest 5h sequence ( Figure 1B ) extended 80 bp upstream from the translation initiation codon reported by Hu et al. [18] and was in complete agreement with the cDNA described in the patent literature by Gerald et al. [15] . Despite our extensive screening, we were not able to obtain a fulllength 5h UTR for the Y5 L mRNA, suggesting that there are difficulties associated with cloning this region. This might explain why others have failed in their attempts to identify the Y5 L cDNA [19, 23] .
To provide further evidence that the Y5 L cDNA was not an artifact of the 5h RACE procedure, RT-PCR was performed from human caudate nucleus poly(A) + RNA using OP1 as the forward primer. A PCR fragment of the expected size was obtained and hybridized to an internal oligoprobe (results not shown). This result is consistent with the sequence data obtained earlier by 5h RACE and confirms the existence of the Y5 L mRNA transcript. Moreover, our data are supported by the first Y5 cloning report published by Gerald et al. [15] in which they described the Y5 L sequences isolated from human hippocampus and rat hypothalamus cDNA libraries. It therefore appears that the Y5 L mRNA transcript retains intronic sequence in the mature mRNA.
Pattern of expression of Y5 L mRNA in human brain and peripheral tissues
We next examined the distribution of hY5 L and hY5 S mRNAs in several human brain regions using RT-PCR. Two sets of primers, OP1-SD5 and OP2-SD5, were designed to amplify fragments that are unique to the Y5 L and Y5 S sequences respectively. Southern blotting with an internal oligonucleotide probe indicated the authenticity of the amplicons. As shown in Figure 2 (A), the Y5 L and Y5 S transcripts displayed the same expression pattern. No signal was observed when reverse transcriptase was omitted from the first-strand cDNA conversion, which suggests that the signals observed were not due to any genomic DNA contaminating the RNA. Surprisingly, only low levels of Y5 mRNA were detected in the hypothalamus. This result contrasts with previous in situ hybridization and PCR data that have shown relatively high levels of Y5 mRNA in this brain area [30] . These differences might be explained by the fact that the hypothalamus preparation originated from a single patient. High levels of Y5 mRNA were detected in the caudate nucleus and hippocampus. These findings are consistent with data obtained in Northern blotting and in situ hybridization studies [30, 31] . Woldbye et al. [32] suggested that Y5 receptors mediate the anticonvulsant action of intraventricularly injected NPY on motor convulsions and EEG seizures, which are induced by systemic administration of kainic acid in rats. In addition, Kopp et al. [33] demonstrated that seizure activity regulates gene expression for Y5 receptors in the limbic system. It would thus be of interest to comprehensively map and compare, at a cellular level, the differential distributions of Y5 L and Y5 S mRNA variants in limbic structures. To investigate expression in peripheral tissues, we performed PCR with a set of normalized human tissue cDNAs. As shown in Figure 2 (B), Y5 S and Y5 L mRNAs displayed different expression patterns. For Y5 S , the highest level of expression was found in testis. Colon, ovaries, prostate and spleen showed intermediate levels, while a very low level of expression was found in small intestine. In this experiment, no expression was detected in leucocytes. In contrast with Y5 S , Y5 L transcripts were expressed at similar levels in colon, spleen and testis. Lower levels were found in leucocytes and prostate, whereas no ex-Pharmacology of short and long neuropeptide Y Y5 receptor isoforms pression was detected in the small intestine. These data suggest that the expression of Y5 mRNA isoforms occurs in a tissuespecific manner. Moreover, Y5 receptor gene expression may be under the control of multiple promoters that are activated in a tissue-specific manner.
Initiation of translation on Y5 L mRNA
According to a widely accepted model proposed by Kozak [34] , recognition by eukaryotic ribosomes of the translation initiation codon generally proceeds by a scanning mechanism in which the 40 S ribosomal subunit migrates from the capped mRNA 5h end to the first AUG triplet that is found in a favourable context. The efficiency of initiation from an AUG codon is increased if it lies in an optimal sequence context, which in higher eukaryotes is CA\GCCAUGG, with purines being critical at positions k3 and j4 [35] . Surprisingly, the sequence ACAUAUGU surrounding the AUG codon in Y5 L mRNA assigned by Gerald et al. [15] as the initiator codon does not conform to the typical Kozak consensus sequence. The in-frame AUG located 30 nucleotides downstream lies in a much better sequence context, i.e. UAAUAUGG, and would give rise to the protein described by Hu et al. [18] . In order to investigate the initiation of translation on Y5 L mRNA, wild-type Y5 L cDNA and two Y5 L cDNA mutants, MATG1 and MATG2, respectively lacking the first and the second putative initiation start codon, were cloned and transiently expressed in COS-7 cells. The levels of expression were measured by saturation binding experiments carried out on membrane preparations using ["#&I]PYY.
As shown in Figure 3 , the three constructs exhibited similar levels of expression. If initiation was limited to the second AUG codon, no protein would be synthesized with the mutant construct MATG2. Therefore initiation of translation on Y5 L mRNA can start at the first AUG, giving rise to a Y5 L receptor with an Nterminal 10-amino-acid extension when compared with the Y5 S receptor. In addition, the binding equilibrium dissociation constants (K D ) for binding of ["#&I]PYY to COS-7 cells expressing either Y5 L or Y5 S receptors were nearly identical (1.3 nM and 1.5 nM respectively ; Figure 3) . Finally, functional responses to NPY were measured using a CRE-luciferase reporter gene assay. As shown in Figure 4 , the two receptor isoforms displayed very similar dose-dependent responses, with IC &! values for NPY of 1.3 nM for Y5 L and 1.7 nM for Y5 S .
Characterization of NPY Y5 receptors in COS-7 cells
A potential influence of the 10-amino-acid extension upon the pharmacological profile of the Y5 S and Y5 L receptor isoforms was then tested. As shown in Figure 5 , the two isoforms exhibited a similar pharmacological profile for a selection of six chemically diverse compounds : PYY NPY PP CGP71683A Synaptic 34 Banyu 6 GR231118. There was indeed a strong correlation when the affinities determined at each receptor isoform (r l 0.98, P 0.0001, n l 8) were compared. As anticipated, the selective Y1 receptor antagonists BIBP3226 and BIBO3304, and the Y2 selective antagonist BIIE0246, showed poor affinities (in the micromolar range) for both receptor isoforms.
Effects of upstream AUG codons
AUG codons located in the 5h UTR are well known to be involved in the translational regulation of gene expression [36] . Analysis of the 50 bp upstream from the start codon on Y5 L mRNA showed an in-frame AUG followed directly by a stop codon, and an out-of-frame AUG that initiates an open reading frame encoding a 16-amino-acid polypeptide. To directly assess the effects of the two upstream AUG triplets on Y5 L mRNA translation, the Y5 L coding region flanked by 50 bp from the 5h UTR was cloned. Site-directed mutagenesis was then performed to remove one (pUY5 L 1) or both (pUY5 L 2) ATGs, as depicted in Figure 6 . The constructs were transiently expressed in COS-7 cells and the levels of expression were measured by saturation binding experiments carried out on membrane preparations using ["#&I]PYY. Expression levels were corrected for variable transfection efficiencies by co-transfection with a plasmid directing the expression of β-galactosidase. As shown in Figure  6 , there was no significant difference between the expression levels of the parent and the mutated constructs. A similar result was obtained with the construct lacking any 5h UTR. Together, these results indicate that neither of the upstream AUG codons have any dramatic effect on expression, since their removal did not enhance Y5 receptor expression.
Conclusions
In conclusion, we have confirmed the authenticity of the Y5 L mRNA. Moreover we have shown that this transcript can give rise to a receptor with an N-terminal 10-amino-acid extension when compared with the Y5 S receptor. Although the two receptor isoforms have similar pharmacological profiles, Y5 L and Y5 S mRNAs are differentially expressed. These results suggest that alternative splicing in the 5h UTR of the human NPY Y5 receptor gene could play a role in regulating the level of receptor in a tissue-specific manner.
